Nanox.AI's Investigational HealthAVC Solution Demonstrates 98.3% Sensitivity And 96.6% Specificity In Evaluable CT Scans

• Nanox.AI's Investigational AVC Solution Demonstrated 98.3% Sensitivity and 96.6% Specificity in Evaluable CT Scans.
• Findings Highlight the Potential of AI to Identify Previously Unreported Aortic Valve Calcification Using Existing Routine CT Scans.
• Findings published in the peer-reviewed journal JACC: Advances.
  
  
  
   

PETACH TIKVA, Israel, Nov.2, 2026(GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (("Nanox" or the "Company", NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced that updated clinical data on NanoxAILtd’s("Nanox.AI")aortic valve calcification (AVC) AI solution was presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference, taking place October 31 to November 3, 2026, in San Diego, California.

Nanox.AI’s HealthAVC solution is intended to serve as a non-invasive, post-processing software application that detects and quantifies calcified plaques in the aortic valve. The software analyzes non-gated, non-contrast chest computed tomography (CT) images acquired during routine clinical care and provides a numeric aortic valve calcium score, a sex-based categorization, and a visual indication of the result. The HealthAVC device is being developed for the use by clinicians to assist in the detection and quantification of aortic valve calcification, supporting early identification of patients who may benefit from cardiovascular evaluation, ongoing monitoring, and potential consideration for TAVR. The solution is under development and is not yet cleared for clinical use or commercially available